Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells

American Journal of Pathology

Volumn 158, Issue 1, 2001, Pages 265-273

  Dunk, C ^a   Ahmed, A ^a  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; NITRIC OXIDE; THYMIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; CELL SELECTION; CHEMOLUMINESCENCE; DNA SYNTHESIS; DOSE RESPONSE; ENZYME INHIBITION; ENZYME REGULATION; MITOGENESIS; ORGANOGENESIS; PRIORITY JOURNAL; TUMOR CELL;

EID: 0035145030     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63965-X     Document Type: Article

References (41)

1. The biology of vascular endothelial growth factor
2. The fms like tyrosine kinase a receptor for vascular endothelial growth factor
3. Identification of KDR tyrosine kinase as a receptor for vascular endothelial growth factor
4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
5. Inhibition of tumour growth and metastasis by an immunoneutralizing antibody to vascular endothelial growth factor/vascular permeability factor
6. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
7. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
8. Production of vascular endothelial growth factor by human tumours inhibits the functional maturation of dendritic cells
9. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
10. The vascular endothelial growth factor receptor flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
11. Role of VEGF receptor (Flt-1) in mediating calcium dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells
12. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells. Role of flt-1
13. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis
14. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells
15. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR
16. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours
17. Expression of vascular endothelial growth factor and its receptors flt-1 and KDR in ovarian carcinoma
18. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer
19. Expression of VEGF-C and activation of its receptors VEGR-2 and VEGFR-3 in placenta: Decreased expression in IUGR
20. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells
21. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: A comparison with the human bladder cancer derived epithelial cell line T24/83
22. Functional characterisation of the spontaneously transformed human umbilical vein endothelial cell line ECV304: Use in an in vitro model of angiogenesis
23. VEGF receptor-1 (Flt-1) activation releases nitric oxide that suppresses growth and promotes organisation of endothelial cells
24. Actin fibre formation stimulated by vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) in ECV304 cells
25. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
26. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor
27. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-y and migration of endothelial cells expressing Flt-1
28. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) augments nitric oxide release from quiescent rabbit and human vascular endothelium
29. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase
30. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate
31. G-nitro-L-arginine and L-arginine on experimental pulmonary metastasis in mice
32. Increased gene expression for VEGF and the VEGF receptors KDR/Flk-1 and Flt-1 in lungs exposed to chronic hypoxia: Modulation of gene expression by nitric oxide
33. Exogenous, basal, and flow induced nitric oxide production and endothelial cell proliferation
34. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
35. Endothelial damage induced by NO: Synergism with reactive oxygen species
36. Nitric oxide is involved in the regulation of angiogenesis
37. Role of nitric oxide in growth of solid tumours: A balancing act
38. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium
39. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells
40. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
41. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice